secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2025-11-24T23:59:59+00:00
Accession:  0001193125-25-292155
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verrica raises ~$50M in PIPE to retire OrbiMed debt, extend runway into mid-2027
--------------------------------------------------------------------------------

- Gross proceeds of ~$50M from sale of 6.5M shares, 5.3M pre-funded warrants, and 2.95M Series C warrants.
- $35M of net proceeds to fully repay OrbiMed credit facility ($50M drawn); remaining for working capital.
- Cash runway extended into mid-2027; Q3 2025 cash balance was $21.1M.
- Caligan Partners anchors financing, gets right to designate a Class I board member post-closing.
- Series C warrants exercisable at $6.315/share, expire 5 years from close; pre-funded at $0.0001/share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312525292155/0001193125-25-292155-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312525292155/d692687d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-292155

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer